Drug Trial Radar · NCT04006457
Long-Term PF-06651600 for the Treatment of Alopecia Areata
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,057
Actual
Start
Jul 18, 2019
Primary completion
Jun 25, 2024
Study completion Feb 26, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jul 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug. A sub-study of approximately 60 adult patients who are participating in the B7981032 study will be conducted at select sites in the US, Australia and Canada. The sub-study will evaluate the immune response to tetanus and meningococcal vaccines in patients who have received a minimum of 6 months of 50 mg PF-06651600.
Conditions
- Alopecia Areata
Interventions
PF-06651600Drug
50 mg oral tablets/capsules
Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccineBiological
Single intramuscular injection administered to patients participating in the vaccine sub-study
Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccineBiological
Single intramuscular injection administered to patients participating in the vaccine sub-study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Study: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Until Follow-up VisitTime frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
- Main Study: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) Leading to Discontinuation Until Follow-up VisitTime frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
- Main Study: Number of Participants According to Categorization of Vital Signs Data Until Follow-up VisitTime frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
- Main Study: Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Values Until Follow-up VisitTime frame: From start of study intervention (Day 1) until follow-up visit (4 weeks after last dose in Treatment period 1) (Up to Month 40)
- Vaccine Sub-study: Percentage of Participants With Tetanus Booster ResponseTime frame: Month 1
Locations
144 sites in 17 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham Hosptial Outreach Lab
Birmingham, Alabama
The University of Alabama at Birmingham
Birmingham, Alabama
The University of Alabama at Birmingham, Department of Dermatology
Birmingham, Alabama
Mosaic Dermatology
Beverly Hills, California
Univ of California, Irvine, Dermatology Clinical Research Center
Irvine, California
Dermatology Specialists Inc.
Murrieta, California
University of California, San Francisco
San Francisco, California
Kaiser Permanente Clinical Trials Unit
San Francisco, California
Southern California Dermatology, Inc.
Santa Ana, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
University of Colorado Hospital Clinical and Translational Research Center
Aurora, Colorado
University of Colorado Hospital Outpatient Pavilion
Aurora, Colorado
Yale School of Medicine, Yale Center for Clinical Investigations
New Haven, Connecticut
Medstar Georgetown University Hospital - Department of Otolaryngology
Washington D.C., District of Columbia
Medstar Georgetown University Hospital-Dept of Otolaryngology
Washington D.C., District of Columbia
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Medstar Georgetown University Hospital - Department of Pediatrics
Washington D.C., District of Columbia
Siperstein Dermatology Group
Boynton Beach, Florida
Park Avenue Dermatology
Orange Park, Florida
ForCare Clinical Research
Tampa, Florida
Velocity Clinical Research - Boise
Meridian, Idaho
Northwestern Medical Group
Chicago, Illinois
Northwestern Medicine Diagnostic Testing Center
Chicago, Illinois
Northwestern Medicine
Chicago, Illinois
Northwestern Memorial Hospital Investigational Drug Service Pharmacy
Chicago, Illinois
Summit Dermatology and Aesthetic Surgery (in c/o TrialSpark, Inc)
Oakbrook Terrace, Illinois
NorthShore University HealthSystem Dermatology Clinical Trials Unit
Skokie, Illinois
Southern Illinois University School of Medicine
Springfield, Illinois
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Medstar Georgetown University Hospital - Department of Dermatology
Chevy Chase, Maryland
Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
Boston, Massachusetts
University of Minnesota Clinical Research Unit (CRU)
Minneapolis, Minnesota
University of Minnesota Lillehei Clinical Research Unit (LCRU)
Minneapolis, Minnesota
University of Minnesota Medical Center, Investigational Drug Services Attn: Darlette Luke
Minneapolis, Minnesota
Skin Specialists, PC (Schlessinger MD)
Omaha, Nebraska
Schweiger Dermatology, P.C.
Verona, New Jersey
NYU School of Medicine, The Ronald O. Perelman Department of Dermatology
New York, New York
Pura Dermatology (in c/o TrialSpark, Inc)
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Showing 40 of 144 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.